Australian TGA Approves Illuccix® for Prostate Cancer Imaging

MELBOURNE, Australia, Nov. 1 (Korea Bizwire) — Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the Australian Therapeutic Goods Administration (TGA) has approved Illuccix® (TLX591-CDx), the Company’s lead prostate cancer imaging product. Illuccix (Kit for the preparation of 68Ga PSMA-11 Injection) is a positron emission tomography (PET) agent for the diagnostic imaging of men [...]